Radiopharm Theranostics Signs Agreement With NorthStar Medical Radioisotopes for the Supply of Non-Carrier Added (n.c.a.) Actinium-225

3 years ago

SYDNEY & BELOIT, Wis.--(BUSINESS WIRE)--Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and…

Flashlight Capital Issues Letter to KT&G Shareholders

3 years ago

Intends to Provide Shareholders an Opportunity to Add Independent Directors with Capital Markets Acumen, Operational Expertise and Investor Perspectives to…

Energy Vault Issued Notice of Award From Meadow Creek Solar Farm for a 250MW/500MWh Grid-connected Battery in Victoria, Australia

3 years ago

AEMO Advanced Grid Studies for 500MWh Energy Vault BESS Solution kicks off in Australia First BESS award for short duration…

Fidelity D & D Bancorp, Inc. Reports Third Quarter 2022 Financial Results

3 years ago

DUNMORE, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Fidelity D & D Bancorp, Inc. (NASDAQ: FDBC) and its banking subsidiary,�The…

VIQ Solutions Partners with ORdigiNAL Accelerating Channel Distribution of its Innovative Documentation Technology in Europe and Asia Pacific

3 years ago

ORdigiNAL�s vast dealer network to resell VIQ�s NetScribe� and FirstDraft�, powered by aiAssist� to speed documentation of recorded content PHOENIX,…

VIQ Solutions Partners with ORdigiNAL Accelerating Channel Distribution of its Innovative Documentation Technology in Europe and Asia Pacific

3 years ago

ORdigiNAL�s vast dealer network to resell VIQ�s NetScribe� and FirstDraft�, powered by aiAssist� to speed documentation of recorded content PHOENIX,…

VIQ Solutions Partners with ORdigiNAL Accelerating Channel Distribution of its Innovative Documentation Technology in Europe and Asia Pacific

3 years ago

ORdigiNAL�s vast dealer network to resell VIQ�s NetScribe� and FirstDraft�, powered by aiAssist� to speed documentation of recorded content PHOENIX,…

BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America

3 years ago

BRUKINSA� received Marketing Authorization as a treatment for rare blood cancers in six countries in Central and South America CAMBRIDGE,…

BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America

3 years ago

BRUKINSA� received Marketing Authorization as a treatment for rare blood cancers in six countries in Central and South America CAMBRIDGE,…

BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America

3 years ago

BRUKINSA� received Marketing Authorization as a treatment for rare blood cancers in six countries in Central and South America CAMBRIDGE,…